• X Mile

  Participated · Series C · Aug 2026

  Founded in February 2019, X Mile started as a staffing platform matching workers with employers in non-desk industries and has since broadened into software, AI tools, M&A advisory, and vehicle sales for operators. The platform now reports more than 1.2 million registered job seekers and over 30,000 client business locations. X Mile’s digital transformation platform for transportation and logistics operators has grown annual recurring revenue by more than 90% year-on-year. The company plans to expand its vertical AI product line for logistics, construction, and manufacturing, grow its M&A and business-support capabilities, and deepen partnerships with major corporations. Its recent Series C increases total funding to JPY6.96 billion and is intended to support product expansion and acquisitions that add complementary products and teams.

• Tailor

  Participated · Series A · Nov 2025

  Tailor provides a composable, headless ERP system designed for modern retail, e-commerce, and supply-chain businesses. The cloud platform offers modular tools for inventory management, omnichannel order orchestration, production tracking, and warehouse management, allowing brands to automate workflows and adapt quickly to operational changes. Current customers include Universal Jewelry. With offices in San Francisco and Tokyo, the company is using its latest capital to expand U.S. operations, roll out enterprise implementations in Japan, and deepen customer-success and ecosystem partnerships. Tailor also plans to continue building out additional modular ERP components to broaden its product suite. To date, the company has secured $37 million in Series A funding, underscoring strong investor confidence in its approach to next-generation retail infrastructure.

• Pathalys Pharma

  Participated · Series B · Aug 2024

  Pathalys Pharma is a late-stage clinical biopharmaceutical company based in Research Triangle Park, NC, focused on therapies for end-stage kidney disease (ESKD). Its initial asset is upacicalcet, a novel calcimimetic intended to improve treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is running two ongoing clinical trials of upacicalcet and intends to use new financing to finalize those studies. Pathalys plans to execute an NDA filing with the U.S. Food and Drug Administration and accelerate preapproval commercialization preparations. Beyond upacicalcet, the company continues to identify additional needs and potential therapeutic solutions for patients with ESKD. The recent financing is intended to support late-stage development, regulatory submission, and commercialization readiness. Pathalys Pharma is a private, late-stage clinical biopharmaceutical company focused on developing advanced therapeutics for end-stage kidney disease (ESKD). Its lead asset is upacicalcet, a novel calcimimetic aimed at improving treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is led by CEO Neal Fowler and continues to identify other high-priority needs and potential solutions for patients with ESKD. Pathalys has entered a collaboration with Launch Therapeutics to advance the phase 3 clinical trials for upacicalcet; Launch Therapeutics is backed by funds managed by Carlyle and Abingworth. The recently announced financing will support two phase 3 trials, regulatory registration efforts, and pre-commercialization activities for upacicalcet. Pathalys remains a privately held, late-stage clinical-stage biopharma working toward commercialization of its initial asset.

• Renalys Pharma

  Participated · Series A · Jul 2024

  Renalys Pharma is a Tokyo-based late-stage clinical biopharmaceutical company focused on developing innovative therapeutics for renal disease in Japanese and Asian patients. The company holds rights to sparsentan via a licensing agreement with Travere Therapeutics. Renalys aims to address “drug loss” by catalyzing access to new treatments for kidney disease across the region. It submitted an IND for sparsentan to Japan’s PMDA in April 2024 and plans to initiate an open-label registrational Phase III study in Q2 2024. The Phase III program targets IgA nephropathy, a prevalent kidney disease in Japan and Asia, with anticipated urine protein/creatinine ratio endpoint results in the second half of 2025. Renalys is led by CEO BT Slingsby and is privately held.

No current team members are available.